AMENDMENTS TO THE CLAIMS

1. (original) A method, comprising:

a) providing;

i) target cells,

ii) a library comprising a plurality of ligands, wherein at least one ligand is capable of binding so as to cause a response from at least a subset of said target cells, and

iii) an indicator;

b) contacting the target cells with said ligands of said library to create treated target cells, under conditions such that a subset of said treated target cells is activated;

c) exposing said treated target cells to said indicator, under conditions such that the at least one activated target cell is detected to create a detected activated target cell;

d) collecting said detected activated target cell to create a collected activated target cell; and

e) recovering said ligand from said collected activated target cell.

2. (original) The method of claim 1, wherein said library is a phage display library.

3. (original) The method of claim 1, wherein said target cell is a cancer cell.

4. (currently amended) The ~~target cell~~ method of claim 3, wherein said cancer cell is an acute lymphoblastic leukemia cell.

5. (currently amended) The method of claim 4, wherein said acute lymphoblastic leukemia cell ~~of claim 4, wherein said cell~~ is selected from the group consisting of a JURKAT cell, a MOLT-4 cell, a TALL-104 cell and a patient ALL cell.

6. (original) The method of claim 1, wherein said cellular response comprises a response selected from the group consisting of apoptosis, proliferation, differentiation, adhesion, migration, cytokine secretion, and cessation of such said processes.

7. (original) The method of claim 1, wherein said cellular response comprises a response selected from the group consisting of phosphorylation, dephosphorylation, calcium flux, target

molecule cleavage, protein-protein interaction, protein-nucleic acid interaction, nucleic acid-nucleic acid interaction, and production of detectable fluorescence.

8. (currently amended) The method of ~~claim 1,~~ claim 6, wherein said cellular response comprises apoptosis and wherein said indicator comprises fluorescent-labeled Annexin V.

9-16. (canceled)